Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-03-16 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES
Foreign Filer Report
2021-03-16 English
Divestment of Viela shareholding completed
M&A Activity Classification · 99% confidence The document is identified by the 'RNS Number' header and contains a date stamp typical of regulatory news services. The content announces the completion of a 'Divestment of Viela shareholding' and provides financial considerations ($775m cash proceeds). This is a specific corporate action announcement related to asset disposal/financing, but it is distributed via RNS. Since the core event is a divestment/transaction, it relates to capital structure changes or asset sales. Given the options, 'Capital/Financing Update' (CAP) is a strong fit for the financial impact of a divestment, but the document is explicitly distributed via RNS and is a general regulatory announcement. Since the document is short and is a direct announcement of a corporate event via the RNS system, and 'Divestment' is a form of asset transaction, it fits best under the general regulatory announcement category (RNS) or potentially Capital/Financing Update (CAP). However, the presence of 'RNS Number' and the structure strongly suggest a general regulatory filing. Let's check the definitions: 'CAP' is for fundraising/financing activities. Divestment is the opposite but related to capital structure. 'RNS' is the fallback for miscellaneous filings. Given the nature of the announcement (completion of a divestment), it is a specific corporate event disclosure. Since there isn't a specific 'Divestment' code, and it's clearly an RNS release, I will classify it as RNS, as it is a general regulatory announcement distributed through that channel, which is often the case for non-standard disclosures.
2021-03-16 English
US supply agreement for additional AZD7442 doses
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and contains a date stamp (16 March 2021) and a closing statement referencing RNS, the news service of the London Stock Exchange, and the Financial Conduct Authority (FCA). The content is a press release announcing a modification to an existing agreement with the US Government regarding the supply of the COVID-19 treatment AZD7442. This type of immediate, material corporate news release, especially one originating from the RNS system, typically falls under general regulatory announcements or news wires. Since it is not a formal financial report (like 10-K or IR), a specific management disclosure (like MANG or DIRS), or a proxy/dividend notice, the most appropriate classification is the general regulatory announcement category, RNS.
2021-03-16 English
425 Filing
Regulatory Filings
2021-03-12 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2021-03-09 English
Director/PDMR Shareholding
Remuneration Information Classification · 99% confidence The document is identified by the RNS Number (6809R) and the header 'Transactions by Persons Discharging Managerial Responsibilities'. It details the granting of share awards (stock options/grants) to senior executives (Pascal Soriot, CEO, and Marc Dunoyer, CFO) under specific company plans (AZDBP and AZPSP). This type of mandatory disclosure regarding insider transactions by management falls directly under the definition of Director's Dealing (DIRS). Although it references the Annual Report for performance details, the core content is the transaction notification itself.
2021-03-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.